Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
Фаза 3
Прекращено
NCT03068130
| Заболевание | Pulmonary Hypertension |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Biogen |
|---|
| Статус | Прекращено |
|---|
| Участники | 261 участн. |
|---|
| Вмешательство | Bardoxolone methyl |
|---|
| Дата начала | 18.04.2017 |
|---|
| Дата завершения | 30.09.2020 |
|---|
| Публикация результатов | 12.10.2023 |
|---|
Кратко
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.
Long Term Safety as Measured by Incidence and Severity of Adverse Events During the Duration of the Study
From time of first dose until the final visit, up to 172 weeks · Participants
| Bardoxolone Methyl | 232 Participants |
|---|
| Bardoxolone Methyl | 89 Participants |
|---|
| Bardoxolone Methyl | 106 Participants |
|---|
| Bardoxolone Methyl | 42 Participants |
|---|
| Bardoxolone Methyl | 96 Participants |
|---|
| Bardoxolone Methyl | 94 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.